Nanotechnology in diagnosis and treatment of coronary artery disease

Nanomedicine

Volumn 11, Issue 5, 2016, Pages 513-530

  Karimi, Mahdi ^a   Zare, Hossein ^b   Bakhshian Nik, Amirala ^c   Yazdani, Narges ^b   Hamrang, Mohammad ^b   Mohamed, Elmira ^b   Zangabad, Parham Sahandi ^d   Basri, Seyed Masoud Moosavi ^e,f   Bakhtiari, Leila ^b   Hamblin, Michael R ^g,h,i  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d SHARIF UNIVERSITY OF TECHNOLOGY   (Iran)

^e INSTITUTE FOR RESEARCH IN FUNDAMENTAL SCIENCES IPM   (Iran)

^f SHAHID BEHESHTI UNIVERSITY   (Iran)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

atherosclerosis; coronary artery disease; nanocarriers; nanotechnology; restenosis; stent coatings; vulnerable plaque

Indexed keywords

DACTINOMYCIN; DENDRIMER; DEXAMETHASONE; EVEROLIMUS; LIPOSOME; MAGNETIC NANOPARTICLE; NANOCOATING; PACLITAXEL; RAPAMYCIN; TACROLIMUS; ZOTAROLIMUS; DRUG CARRIER; NANOPARTICLE;

CERAMICS; CORONARY ARTERY DISEASE; GENE THERAPY; HUMAN; MICELLE; MOLECULAR IMAGING; NANOTECHNOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; DIAGNOSTIC IMAGING; PATHOLOGY; PLAQUE, ATHEROSCLEROTIC; PROCEDURES;

CORONARY ARTERY DISEASE; DRUG CARRIERS; HUMANS; NANOPARTICLES; NANOTECHNOLOGY; PLAQUE, ATHEROSCLEROTIC;

EID: 84962616693     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.16.3     Document Type: Review

References (110)

1. Brito L, Amiji M. Nanoparticulate carriers for the treatment of coronary restenosis. Int. J. Nanomedicine 2, 143 (2007
2. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J. Intern. Med. 276(6), 618-632 (2014
3. Cominacini L, Garbin U, Mozzini C et al. The atherosclerotic plaque vulnerability: focus on the oxidative and endoplasmic reticulum stress in orchestrating the macrophage apoptosis in the formation of the necrotic core. Curr. Med. Chem. 22(13), 1565-1572 (2015
4. Naghavi M, Libby P, Falk E et al. From vulnerable plaque to vulnerable patient a call for new definitions and risk assessment strategies: part I. Circulation. 108(14), 1664-1672 (2003
5. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 473, 317-325 (2011
6. Lewis DR, Kamisoglu K, York AW, Moghe PV. Polymerbased therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 3, 400-420 (2011
7. Vasir JK, Reddy MK, Labhasetwar VD. Nanosystems in drug targeting: opportunities and challenges. Curr. Nanosci. 1, 47-64 (2005
8. Scott NA. Restenosis following implantation of bare metal coronary stents: pathophysiology and pathways involved in the vascular response to injury. Adv. Drug Deliv. Rev. 58, 358-376 (2006
9. Rhee J-W, Wu JC. Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc. Med. 23, 39-45 (2013
10. Khan W, Farah S, Domb AJ. Drug eluting stents: developments and current status. J. Control. Release. 161(2), 703-712 (2012
11. Ferrero V, Tomai F, Versaci F et al. Long-Term results of immunosuppressive oral prednisone after coronary angioplasty in non-diabetic patients with elevated C-reactive protein levels. EuroIntervention. 5(2), 250-254 (2009
12. Rodriguez AE, Granada JF, Rodriguez-Alemparte M et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J. Am. College Cardiol. 47(8), 1522-1529 (2006
13. Banai S, Chorny M, Gertz SD et al. Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. Biomaterials 26, 451-461 (2005
14. Masuda S, Nakano K, Funakoshi K et al. Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. J. Atheroscl. Thromb. 18, 1043-1053 (2011
15. Bhargava B, Reddy NK, Karthikeyan G et al. A novel paclitaxel-eluting porous carbon-carbon nanoparticle coated, nonpolymeric cobalt-chromium stent: evaluation in a porcine model. Cathet. Cardiovasc. Intervent. 67, 698-702 (2006
16. Räthel T, Mannell H, Pircher J, Gleich B, Pohl U, Krötz F. Magnetic stents retain nanoparticle-bound antirestenotic drugs transported by lipid microbubbles. Pharm. Res. 29, 1295-1307 (2012
17. Joner M, Morimoto K, Kasukawa H et al. Site-specific targeting of nanoparticle prednisolone reduces in-stent restenosis in a rabbit model of established atheroma. Arterioscler. Thromb. Vasc. Biol. 28, 1960-1966 (2008
18. Fishbein I, Alferiev I, Bakay M et al. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation 117, 2096-2103 (2008
19. Barlis P, Regar E, Serruys PW et al. An optical coherence tomography study of a biodegradable vs. durable polymercoated limus-eluting stent: a LEADERS trial sub-study. Eur. Heart J. 30, ehp480 (2009
20. Matsumoto D, Shite J, Shinke T et al. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography. Eur. Heart J. 28(8), 961-967 (2007
21. Otake H, Shite J, Ikeno F et al. Evaluation of the peri-strut low intensity area following sirolimus-And paclitaxel-eluting stents implantation: insights from an optical coherence tomography study in humans. Int. J. Cardiol. 157(1), 38-42 (2012
22. Patrono C, Andreotti F, Arnesen H et al. Antiplatelet agents for the treatment and prevention of atherothrombosis. Eur. Heart J. 32(23), 2922-2932 (2011
23. Rollini F, Franchi F, Angiolillo DJ. Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat. Rev. Cardiol. 13, 11-27 (2016
24. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat. Rev. Cardiol. 12(1), 30-47 (2015
25. Tsoi M-F, Cheung C-L, Cheung TT et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: meta-Analysis of large randomised controlled trials. Sci. Rep. 5, 13204 (2015
26. Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review. JAMA. 310(2), 189-198 (2013
27. Olsen A-MS, Gislason GH, Mcgettigan P et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 313(8), 805-814 (2015
28. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-Artery stents. N. Engl. J. Med. 368(3), 254-265 (2013
29. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N. Engl. J. Med. 371(23), 2155-2166 (2014
30. Kharlamov AN. Plasmonic photothermal therapy for atheroregression below Glagov threshold. Fut. Cardiol. 9(3), 405-425 (2013
31. Kharlamov AN, Tyurnina AE, Veselova VS, Kovtun OP, Shur VY, Gabinsky JL. Silica-gold nanoparticles for atheroprotective management of plaques: results of the NANOM-FIM trial. Nanoscale. 7(17), 8003-8015 (2015
32. Patel DN, Bailey SR. Nanotechnology in cardiovascular medicine. Cathet. Cardiovasc. Intervent. 69, 643-654 (2007
33. Tang C, Amin D, Messersmith PB, Anthony JE, Prudhomme RK. Polymer directed self-Assembly of pHresponsive antioxidant nanoparticles. Langmuir. 31(12), 3612-3620 (2015
34. Gundogan B, Tan A, Farhatnia Y, Alavijeh MS, Cui Z, Seifalian AM. Bioabsorbable stent quo vadis: a case for nanotheranostics. Theranostics 4, 514-533 (2014
35. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4, 145-160 (2005
36. Gupta AS. Nanomedicine approaches in vascular disease: a review. Nanomedicine 7, 763-779 (2011
37. Srinivasan R, Marchant RE, Gupta AS. In vitro and in vivo platelet targeting by cyclic RGD-modified liposomes. J. Biomed. Mater. Res. Part A 93, 1004-1015 (2010
38. Gutman D, Golomb G. Liposomal alendronate for the treatment of restenosis. J. Control. Release. 161(2), 619-627 (2012
39. Van Der Valk FM, Van Wijk DF, Lobatto ME et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 11(5), 1039-1046 (2015
40. Hofmeister LH, Lee SH, Norlander AE et al. Phage-displayguided nanocarrier targeting to atheroprone vasculature. ACS Nano. 9(4), 4435-4446 (2015
41. Haeri A, Sadeghian S, Rabbani S et al. Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. Int. J. Pharmaceut. 455(1), 320-330 (2013
42. Amirbekian V, Lipinski MJ, Frias JC et al. MR imaging of human atherosclerosis using immunomicelles molecularly targeted to macrophages. J. Cardiovasc. Magn. Res. 11, 1-2 (2009
43. Doshi N, Prabhakarpandian B, Rea-Ramsey A, Pant K, Sundaram S, Mitragotri S. Flow and adhesion of drug carriers in blood vessels depend on their shape: a study using model synthetic microvascular networks. J. Control. Release 146, 196-200 (2010
44. Chan JM, Rhee J-W, Drum CL et al. In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc. Natl Acad. Sci. USA 108, 19347-19352 (2011
45. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. J. Control. Release 133, 90-95 (2009
46. Tsukie N, Nakano K, Matoba T et al. Pitavastatinincorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. J. Atheroscl. Thromb. 20, 32-45 (2013
47. Hawker CJ, Frechet JMJ. Preparation of polymers with controlled molecular architecture. A new convergent approach to dendritic macromolecules. J. Am. Chem. Soc. 112, 7638-7647 (1990
48. Nguyen TH, Bryant H, Shapsa A et al. Manganese G8 dendrimers targeted to oxidation-specific epitopes: in vivo MR imaging of atherosclerosis. J. Magn. Res. Imaging. 41(3), 797-805 (2015
49. Liu J, Gu C, Cabigas EB et al. Functionalized dendrimerbased delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials. 34(14), 3729-3736 (2013
50. Spyropoulos-Antonakakis N, Sarantopoulou E, Trohopoulos PN et al. Selective aggregation of PAMAM dendrimer nanocarriers and PAMAM/ZnPc nanodrugs on human atheromatous carotid tissues: a photodynamic therapy for atherosclerosis. Nanoscale Res. Lett. 10(1), 1-19 (2015
51. Nguyen KT, Shukla KP, Moctezuma M et al. Studies of the cellular uptake of hydrogel nanospheres and microspheres by phagocytes, vascular endothelial cells, and smooth muscle cells. J. Biomed. Mater. Res. Part A 88, 1020-1030 (2009
52. Reddy MK, Vasir JK, Sahoo SK, Jain TK, Yallapu MM, Labhasetwar V. Inhibition of apoptosis through localized delivery of rapamycin-loaded nanoparticles prevented neointimal hyperplasia and reendothelialized injured artery. Circulation 1, 209-216 (2008
53. Chorny M, Fishbein I, Forbes S, Alferiev I. Magnetic nanoparticles for targeted vascular delivery. IUBMB Life. 63(8), 613-620 (2011
54. Zohra FT, Medved M, Lazareva N, Polyak B. Functional behavior and gene expression of magnetic nanoparticleloaded primary endothelial cells for targeting vascular stents. Nanomedicine. 10(9), 1391-1406 (2015
55. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 60, 1252-1265 (2008
56. Chen L, Zurita AJ, Ardelt PU, Giordano RJ, Arap W, Pasqualini R. Design and validation of a bifunctional ligand display system for receptor targeting. Chem. Biol. 11, 1081-1091 (2004
57. Chorny M, Fishbein I, Yellen BB et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc. Natl Acad. Sci. USA 107, 8346-8351 (2010
58. Godin B, Hu Y, La Francesca S, Ferrari M. Cardiovascular nanomedicine: challenges and opportunities. In: Molecular and Translational Vascular Medicine. (Eds). Springer, 249-281 (2012
59. Jayagopal A, Linton MF, Fazio S, Haselton FR. Insights into atherosclerosis using nanotechnology. Curr. Atheroscl. Rep. 12(3), 209-215 (2010
60. Van Der Giessen WJ, Lincoff AM, Schwartz RS et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 94, 1690-1697 (1996
61. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stentsa review of available cases from the Research on Adverse Drug events And Reports (RADAR) project. J. Am. Coll. Cardiol. 47, 175-181 (2006
62. Finn AV, Kolodgie FD, Harnek J et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 112, 270-278 (2005
63. Acharya G, Lee CH, Lee Y. Optimization of cardiovascular stent against restenosis: factorial design-based statistical analysis of polymer coating conditions. PLoS ONE 7, e43100 (2012
64. Joo JNH, Nam SH, Nam SH, Baek I, Park J-S. Thermal process for enhancing mechanical strength of PLGA nanoparticle layers on coronary stents. Bull. Korean Chem. Soc. 30, 1985-1988 (2009
65. Tan A, Farhatnia Y, Goh D et al. Surface modification of a polyhedral oligomeric silsesquioxane poly (carbonate-urea) urethane (POSS-PCU) nanocomposite polymer as a stent coating for enhanced capture of endothelial progenitor cells. Biointerphases 8, 23 (2013
66. Jungebluth P, Alici E, Baiguera S et al. Tracheobronchial transplantation with a stem-cell-seeded bioartificial nanocomposite: a proof-of-concept study. Lancet 378, 1997-2004 (2011
67. Bakhshi R, Darbyshire A, Evans JE, You Z, Lu J, Seifalian AM. Polymeric coating of surface modified nitinol stent with POSS-nanocomposite polymer. Colloids Surf. B Biointerfaces 86, 93-105 (2011
68. Pareta RA, Reising AB, Miller T, Storey D, Webster TJ. Increased endothelial cell adhesion on plasma modified nanostructured polymeric and metallic surfaces for vascular stent applications. Biotechnol. Bioeng. 103, 459-471 (2009
69. Miller DC, Haberstroh KM, Webster TJ. Mechanism (s) of increased vascular cell adhesion on nanostructured poly (lactic-co-glycolic acid) films. J. Biomed. Mater. Res. Part A 73, 476-484 (2005
70. Joo J-R, Nam HY, Nam SH, Baek I, Park J-S. A novel deposition method of PLGA nanoparticles on coronary stents. Bull. Korean Chem. Soc. 30, 1085-1087 (2009
71. Liu Y, Wang W, Acharya G, Shim Y-B, Choe ES, Lee CH. Advanced stent coating for drug delivery and in vivo biocompatibility. J. Nanopart. Res. 15, 1-16 (2013
72. Kim TG, Lee H, Jang Y, Park TG. Controlled release of paclitaxel from heparinized metal stent fabricated by layerby-layer assembly of polylysine and hyaluronic acid-g-poly (lactic-co-glycolic acid) micelles encapsulating paclitaxel. Biomacromolecules 10, 1532-1539 (2009
73. Nakano K, Egashira K, Masuda S et al. Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. JACC 2, 277-283 (2009
74. Luderer F, Sternberg K, Rohm HW et al. Biodegradable sirolimus-loaded poly (lactide) nanoparticles as delivery systems for the prevention of restenosis in coronary stent application. Presented at: World Congress on Medical Physics and Biomedical Engineering. 7-12 September 2009, Munich, Germany, 193-196 (2010
75. Zhu D, Jin X, Leng X et al. Local gene delivery via endovascular stents coated with dodecylated chitosanplasmid DNA nanoparticles. Int. J. Nanomedicine 5, 1095 (2010
76. Wieneke H, Dirsch O, Sawitowski T et al. Synergistic effects of a novel nanoporous stent coating and tacrolimus on intima proliferation in rabbits. Cathet. Cardiovasc. Intervent. 60, 399-407 (2003
77. Kollum M, Farb A, Schreiber R et al. Particle debris from a nanoporous stent coating obscures potential antiproliferative effects of tacrolimus-eluting stents in a porcine model of restenosis. Cathet. Cardiovasc. Intervent. 64, 85-90 (2005
78. Rajtar A, Kaluza GL, Yang Q et al. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2, 113-115 (2006
79. Costa JR, Abizaid A, Costa R et al. 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial. JACC 2, 422-427 (2009
80. Ayon AA. Utilization of nanoporous titanium dioxide films on drug-eluting stents. Presented at: Annual Meeting-Society For Biomaterials In Conjunction With The International Biomaterials Symposium. 29, 331 (2006
81. Karagkiozaki VC, Logothetidis SD, Kassavetis SN, Giannoglou GD. Nanomedicine for the reduction of the thrombogenicity of stent coatings. Int. J. Nanomedicine 5, 239 (2010
82. Rajender G, Narayanan NGB. Liquid chromatographytandem mass spectrometry method for determination of Sirolimus coated drug eluting nano porous carbon stents. Biomed. Chromatog. 24, 329-334 (2010
83. Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VSY. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 6, 1952-1967 (2010
84. Popat A, Hartono SB, Stahr F, Liu J, Qiao SZ, Lu GQM. Mesoporous silica nanoparticles for bioadsorption, enzyme immobilisation, and delivery carriers. Nanoscale 3, 2801-2818 (2011
85. Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small 6, 1794-1805 (2010
86. Wang Y, Zhang W, Zhang J, Sun W, Zhang R, Gu H. Fabrication of a novel polymer-free nanostructured drugeluting coating for cardiovascular stents. ACS Appl. Mater. Interfaces 5, 10337-10345 (2013
87. Alviar CL, Tellez A, Wang M et al. Low-dose sirolimuseluting hydroxyapatite coating on stents does not increase platelet activation and adhesion ex vivo. J. Thromb. Thrombolys. 34, 91-98 (2012
88. Sun D, Zheng Y, Yin T, Tang C, Yu Q, Wang G. Coronary drug-eluting stents: from design optimization to newer strategies. J. Biomed. Mater. Res. Part A. 102(5), 1625-1640 (2014
89. Binder RK, Lüscher TF. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?. Eur. Heart J. 36(20), 1207-1211 (2015
90. Bozsak F, Gonzalez-Rodriguez D, Sternberger Z et al. Optimization of drug delivery by drug-eluting stents. PLoS ONE. 10(6), 1-29 (2015
91. Yu M, Xu B, Kandzari DE et al. First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial. Cathet. Cardiovasc. Intervent. 83(3), 405-411 (2014
92. Jin X, Mei L, Song C et al. Immobilization of plasmid DNA on an anti-DNA antibody modified coronary stent for intravascular site-specific gene therapy J. Gene Med. 10(4), 421-429 (2008
93. Yin RX, Yang DZ, Wu JZ. Nanoparticle drug- And geneeluting stents for the prevention and treatment of coronary restenosis. Theranostics 4, 175-200 (2014
94. Kim TG, Lee Y, Park TG. Controlled gene-eluting metal stent fabricated by bio-inspired surface modification with hyaluronic acid and deposition of DNA/PEI polyplexes. Int. J. Pharmaceut. 384, 181-188 (2010
95. Paul A, Shao W, Shum-Tim D, Prakash S. The attenuation of restenosis following arterial gene transfer using carbon nanotube coated stent incorporating TAT / DNA Ang1 + Vegf nanoparticles DESIGN : NP-CNT based stent for arterial gene delivery. Biomaterials 33, 7655-7664 (2012
96. Dweck MR, Jones C, Joshi NV et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation. 125(1), 76-86 (2012
97. Aikawa E, Nahrendorf M, Figueiredo J-L et al. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 116(24), 2841-2850 (2007
98. Nguyen PK, Nag D, Wu JC. Molecular imaging of cardiovascular disease. In: Translational Cardiology: Molecular Basis of Cardiac Metabolism, Cardiac Remodeling, Translational Therapies and Imaging Techniques. Springer, 485-531 (2012
99. Flögel U, Ding Z, Hardung H et al. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 118(2), 140-148 (2008
100. Ye Y-X, Calcagno C, Binderup T et al. Imaging macrophage and hematopoietic progenitor proliferation in atherosclerosis. Circulation Res. 117(10), 835-845 (2015
101. Tang J, Lobatto ME, Hassing L et al. Inhibiting macrophage proliferation suppresses atherosclerotic plaque inflammation. Sci. Adv. 1(3), e1400223 (2015
102. Yeager D, Chen Y-S, Litovsky S, Emelianov S. Intravascular photoacoustics for image-guidance and temperature monitoring during plasmonic photothermal therapy of atherosclerotic plaques: a feasibility study. Theranostics. 4(1), 36 (2014
103. Laufer E, Winkens M, Corsten M, Reutelingsperger C, Narula J, Hofstra L. PET and SPECT imaging of apoptosis in vulnerable atherosclerotic plaques with radiolabeled Annexin A5. Q. J. Nucl. Med. Mol. Imaging. 53(1), 26 (2009
104. De Saint-Hubert M, Bauwens M, Deckers N et al. In vivo molecular imaging of apoptosisand necrosis in atherosclerotic plaquesusing microSPECT-CT and microPET-CT imaging. Mol. Imaging Biol. 16(2), 246-254 (2014
105. Desai MY, Schoenhagen P. Emergence of targeted molecular imaging in atherosclerotic cardiovascular disease. Expert Rev. Cardiovasc. Ther. 7(2), 197-203 (2009
106. Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ. Res. 111(2), 231-244 (2012
107. Jaffer FA, Libby P, Weissleder R. Molecular imaging of cardiovascular disease. Circulation 116, 1052-1061 (2007
108. Jacobin-Valat MJ, Deramchia K, Mornet S et al. MRI of inducible P-selectin expression in human activated platelets involved in the early stages of atherosclerosis. NMR Biomed. 24(4), 413-424 (2011
109. Mccarthy JR, Patel P, Botnaru I, Haghayeghi P, Weissleder R, Jaffer FA. Multimodal nanoagents for the detection of intravascular thrombi. Bioconjug. Chem. 20(6), 1251-1255 (2009
110. Qu M, Mehrmohammadi M, Emelianov S. Sensing the delivery and endocytosis of nanoparticles using magnetophoto-Acoustic imaging. Photoacoustics. 3(3), 107-113 (2015